Please assess the completion status of the following clinical trial:

Trial Title: Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women of at least 18 years of age~* Histologically proven Bladder cancer~* Locally advanced or metastatic disease (stage IV)~* Functional status (ECOG / OMS) ≤ 2~* Relapse after first-line chemotherapy~* Measurable lesions (RECIST criteria)~* Absence of anti-neoplasic treatment in the 4 weeks preceding inclusion.~* Biological levels :~* Neutrophil count \>1,5.109/L.~* Platelets \>100.109/L~* Total serum bilirubin \< 1.5 × ULN~* Clearance of créatinine 40 ml/mm~* If not liver metastasis alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<2.5 × ULN~* With liver alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<5 × ULN~* Signed informed consent~* Both women and men must agree to use a medically acceptable method of contraception throughout the study. Women of childbearing potential must have a negative serum pregnancy test of or less than 7 days before the first perfusion of study.~* France only : Patients affiliated to a social security program~Exclusion Criteria:~* Presence of metastatic brain or meningeal tumors on selection scanner, weither symptomatic or asymptomatic~* Chemotherapy, immunotherapy, or radiotherapy within 4 weeks of inclusion~* Known hypersensitivity to temsirolimus, or its metabolites (as sirolimus), or polysorbate 80 or to their excipients~* Previous malignancy (except for cervical carcinoma in situ, basal cell carcinoma curatively treated) or incidental (≤ pT2) prostate cancer found on a radical cystoprostatectomy material~* The drugs known as CYP3A4/5 inhibitors or inducers will specifically be excluded on the 30th day ( or at least 7 halves-lives, according to the shortest duration) before the first perfusion and throughout the study. Any food known to inhibit CYP3A4/5 (for example grapefruit, grapefruit juice, star-fruit or star-fruit juice) will also be purposely excluded.~* Auto-immune pathology, psychiatric or neurological disorder~* Any unstable medical condition~* Unstable cardiac disease~* Severe renal failure~* Unstable diabetes~* Pregnancy~* Patient enrolled in another therapeutic clinical trial~* Patient unable to follow and comply with the study procedures because of any geographical, social or medical condition~* Patient partially or totally deprived of his civil rights

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temsirolimus (Type: EXPERIMENTAL): Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).